medscape semaglutide (Wegovy) is associated with a 41% reduction in the risk for major adverse cardiovascular events (MACEs) within 6 months of initiation — well before patients achieve substantial weight loss or reach Semaglutide for weight loss |

Lyophilized powder degrades meaningfully without cold-chain discipline

Without intervention, approximately seventy percent of losses return within one year, making early transition planning critical for long-term success

Managing Side Effects and Building Sustainable Habits Common semaglutide side effects include nausea, constipation, vomiting, and diarrhea, most occurring during dose escalation and typically subsiding within 37 days as your body adjusts

I am worried about being on medication long-term. This is an understandable concern, but it should be weighed against the documented health consequences of obesity